Recombinant murine granulocyte colony-stimulating factor protects against acute disseminated Candida albicans infection in nonneutropenic mice

Journal of Infectious Diseases

Volumn 177, Issue 1, 1998, Pages 175-181

  Kullberg, Bart Jan ^a   Netea, Mihai G ^a   Curfs, Jo H A J ^a   Keuter, Monique ^a   Meis, Jacques F G M ^a   Van Der Meer, Jos W M ^a  

^a RADBOUD UNIVERSITY MEDICAL CENTER   (Netherlands)

Author keywords

[No Author keywords available]

Indexed keywords

INTERLEUKIN 1ALPHA; INTERLEUKIN 1BETA; RECOMBINANT GRANULOCYTE MACROPHAGE COLONY STIMULATING FACTOR; TUMOR NECROSIS FACTOR ALPHA;

ACUTE DISEASE; ANIMAL MODEL; ARTICLE; CANDIDA ALBICANS; CANDIDIASIS; CONTROLLED STUDY; FEMALE; HOST RESISTANCE; INFECTION RESISTANCE; MOUSE; MYCOSIS; NONHUMAN; PRIORITY JOURNAL; SUBCUTANEOUS DRUG ADMINISTRATION; SURVIVAL RATE;

EID: 0031975139     PISSN: 00221899     EISSN: None     Source Type: Journal    
DOI: 10.1086/513812     Document Type: Article

References (32)

1. Jarvis WR. Epidemiology of nosocomial fungal infections, with emphasis on Candida species. Clin Infect Dis 1995;20:1526-30.
2. Rex JH, Bennett JE, Sugar AM, et al. A randomized trial comparing fluconazole with amphotericin B for the treatment of candidemia in patients without neutropenia. N Engl J Med 1994;331:1325-30.
3. Kullberg BJ, Van 't Wout JW. Cytokines in the treatment of fungal infections. Biotherapy 1994;7:195-210.
4. Van 't Wout JW, Linde I, Leijh PCJ, Van Furth R. Contribution of granulocytes and monocytes to resistance against experimental disseminated Candida albicans infections. Eur J Clin Microbiol Infect Dis 1988;7:736-41.
5. Souza LM, Boone TC, Gabrilove J, et al. Recombinant human granulocyte colony-stimulating factor: effects on normal and leukemic myeloid cells. Science 1986;232:61-5.
6. Welte K, Bonilla MA, Gillio AP, et al. Recombinant human granulocyte colony-stimulating factor. Effects on hematopoiesis in normal and cyclophosphamide-treated primates. J Exp Med 1987;165:941-8.
7. Platzer E, Welte K, Gabrilove J, et al. Biological activities of human pluripotent colony-stimulating factor on normal and leukemic cells. J Exp Med 1985;162:1788-801.
8. Cohen AM, Hines SK, Korach ES, Ratzkin BJ. In vivo activation of neutrophil function in hamsters by recombinant human granulocyte colony-stimulating factor. Infect Immun 1988;56:2861-5.
9. Matsumoto M, Matsubara S, Matsuno T, Ono M, Yokota T. Protective effect of recombinant human granulocyte colony-stimulating factor (rG-CSF) against various microbial infections in neutropcnic mice. Microbiol Immunol 1990;34:765-73.
10. Polak-Wyss A. Protective effect of human granulocyte colony-stimulating factor (hG-CSF) on Candida infections in normal and immunosuppressed mice. Mycoses 1991;34:109-18.
11. Lehrer RI, Cline MJ. Interactions of Candida albicans with human leukocytes and serum. J Bacteriol 1969;98:996-1004.
12. Kullberg BJ, Van 't Wout JW, Van Furth R. Role of granulocytes in enhanced host resistance to Candida albicans induced by recombinant interleukin-1. Infect Immun 1990;58:3319-24.
13. Kullberg BJ, Van 't Wout JW, Van Furth R. No effect of recombinant human interleukin-1 on the numbers of peripheral blood and peritoneal leukocytes during an acute inflammation. Inflammation 1991;15:457-70.
14. Netea MG, Demacker PNM, Kullberg BJ, et al. Low-density-lipoprotein receptor deficient mice are protected against lethal endotoxinemia and severe Gram-negative infections. J Clin Invest 1996;97:1366-72.
15. Easmon CSF, Cole PJ, Williams AJ, Hastings M. The measurement of opsonic and phagocytic function by Luminol-dependent chemiluminescence. Immunology 1980;41:67-74.
16. Kullberg BJ, Van 't Wout JW, Hoogslraten C, Van Furth R. Recombinant interferon-γ enhances resistance to acute disseminated Candida albicans infection in mice. J Infect Dis 1993;168:436-43.
17. Roilides E, Walsh TJ, Pizzo PA, Rubin M. Granulocyte colony-stimulating factor enhances the phagocytic and bactericidal activity of normal and defective human neutrophils. J Infect Dis 1991;163:579-83.
18. Netea MG, Kullberg BJ, Blok WL, Netea RT, Van der Meer JWM. The role of hypemricemia in the increased cytokine production after lipopolysaccharide challenge in neutropenic mice. Blood 1997;89:577-82.
19. Yamamoto Y, Klein TW, Friedman H, Kimura S, Yamaguchi H. Granulocyte colony-stimulating factor potentiates anti-Candida albicans growth inhibitory activity of polymorphonuclear cells. FEMS Immunol MedMicrobiol 1993;7:15-22.
20. Roilides E, Uhlig K, Venzon D, Pizzo PA, Walsh TJ. Neutrophil oxidative burst in response to blastoconidia and pseudohyphae of Candida albicans: augmentation by granulocyte colony-stimulating factor and interferon-γ. J Infect Dis 1992;166:668-73.
21. Hamood M, Bluche PF, De Vroey C, Corazza F, Bujan W, Fondu P. Effects of recombinant human granulocyte-colony stimulating factor on neutropenic mice infected with Candida albicans: acceleration of recovery from neutropenia and potentiation of anti-C. albicans resistance. Mycoses 1994;37:93-9.
22. Matsumoto M, Matsubara S, Matsuno T, et al. Protective effect of human granulocyte colony-stimulating factor on microbial infection in neutropenic mice. Infect Immun 1987;55:2715-20.
23. Yamamoto Y, Uchida K, Klein TW, Friedman H, Yamaguchi H. Immunomodulators and fungal infections: use of antifungal drugs in combination with G-CSF. In: Friedman H, ed. Microbial infections. New York: Plenum Press, 1992:231-41.
24. Uchida K, Yamamoto Y, Klein TW, Friedman H, Yamaguchi H. Granulocyte-colony stimulating factor facilitates the restoration of resistance to opportunistic fungi in leukopenic mice. J Med Vet Mycol 1992;30:293-300.
25. Arenberg D, Navarro E, Roilides E, et al. Effects of granulocyte colony stimulating factor in experimental hepatosplenic candidiasis in granulocytopenic rabbits [abstract]. In: Proceedings of the 90th annual meeting of the American Society for Microbiology (Anaheim, CA). Washington, DC: ASM, 1990.
26. Herbrecht R, Waller J, Koenig H, Morier P, Letscher V. Synergistic efficacy of recombinant human granulocyte colony-stimulating factor and amphotericin B against disseminated candidosis in non neutropenic mice. J Mycol Med 1996;6:43-8.
27. Graybill JR, Bocanegra R, Luther M. Antifungal combination therapy with granulocyte colony-stimulating factor and fluconazole in experimental disseminated candidiasis. Eur J Clin Microbiol Infect Dis 1995;14:700-3.
28. Görgen I, Hartung T, Leist M, et al. Granulocyte colony-stimulating factor treatment protects rodents against lipopolysaccharide-induced toxicity via suppression of systemic tumor necrosis factor-α. J Immunol 1992;149:918-24.
29. Netea MG, Blok WL, Kullberg BJ, et al. Pharmacological inhibitors of tumor necrosis factor production exert differential effects in lethal endotoxemia and in infection with live microorganisms in mice. J Infect Dis 1995;171:393-9.
30. Karbassi A, Backer JM, Foster JS, Moore RN. Enhanced killing of Candida albicans by murine macrophages treated with macrophage colony-stimulating factor: evidence for augmented expression of mannose receptors. J Immunol 1987:139:417-21.
31. Vitt CR, Fidler JM, Ando D, Zimmerman RJ, Aukerman SL. Antifungal activity of recombinant human macrophage colony-stimulating factor in models of acute and chronic candidiasis in the rat. J Infect Dis 1994;169:369-74.
32. Hume DA, Denkins Y. The deleterious effect of macrophage colony-stimulating factor (CSF-1) on the pathology of experimental candidiasis in mice. Lymphokine Cytokine Res 1992;11:95-8.